Navigation Links
Oncolytics Biotech Inc.'s Research Collaborators to Present,REOLYSIN Clinical Trial Data at ASCO Conference

CALGARY, June 01, 2007 /PRNewswire-FirstCall/ - Research collaborators with Oncolytics Biotech Inc. ("Oncolytics") are scheduled to deliver a poster presentation covering REOLYSIN(R) clinical trial data at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 1-5, 2007 in Chicago. The data cover final results of Oncolytics' U.K. Phase I systemic administration trial.

The poster, entitled "Final Results of a Phase I Study of Wild-Type Oncolytic Reovirus Administered Intravenously to Patients with Advanced Cancer" is scheduled to be presented by Dr. James Spicer of The Royal Marsden Hospital and The Institute of Cancer Research, U.K. on Sunday, June 3, 2007.

The poster will be available on the Oncolytics website on Monday, June 4, 2007.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials to be presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking sta
'"/>




Page: 1 2

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Positive Clinical Data from U.S. Phase I REOLYSIN Trial
2. Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines
3. Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting
4. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
8. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
9. Active Biotech presents new pre-clinical data for the 57-57 project at the 8th World Congress on Inflammation
10. New Positive Pre-clinical Data for Active Biotechs RA Project I-3D
11. Prana Biotechnology Presents New Key Findings on PBT2
Post Your Comments:
(Date:7/23/2014)... , July 23, 2014 On Tuesday, ... ("Plaintiff") filed suit in the 116 th ... , against RegenLab USA, LLC ... Prospective Business Relationships through false and misleading ... Business Disparagement through libel, disparagement, defamation, ...
(Date:7/23/2014)... July 23, 2014 /PRNewswire-iReach/ -- The Centers for Medicare ... Quality Innovation Network-Quality Improvement Organization (QIN-QIO) contract to a ... Effective August 1, WVMI will launch Quality ... , Pennsylvania , ... and Louisiana.  The Network will engage providers and the ...
(Date:7/23/2014)... -- RT Oncology Services Corporation today announced that Craig ... directors. Mr. Mundie is currently senior advisor to the ... projects within the company and on technology strategy and ... officer. Mike Martin , president ... a visionary technology executive. His appointment is part of ...
Breaking Medicine Technology:Announcing a New Regional Approach to Medicare Quality Improvement 2Craig Mundie Joins RainTree Oncology Board of Directors 2Craig Mundie Joins RainTree Oncology Board of Directors 3
... , , WALTHAM, Mass., ... research and advisory firms for pharmaceutical and healthcare issues, finds ... cause the schizophrenia drug market to decrease from $6.3 billion ... States, France, Germany, Italy, Spain, the United Kingdom and Japan. ...
... , , BIRMINGHAM, Ala., Dec. 2 ... cancer. For adults 65 and over, the odds of losing vision are ... are one in six and odds of a woman developing breast cancer ... aging adults by increasing the risk of injuries, depression and inability to ...
Cached Medicine Technology:Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013 2Risk of Vision Loss in Aging Adults is Greater Than Risk of Breast or Prostate Cancer 2
(Date:7/23/2014)... 23, 2014 Recently, Agebc.com has launched ... the company is announcing a promotion of wedding dresses. ... will end at the end of this month. , ... popular styles, like A-line, mermaid, ball-gown, empire, and more. ... and other special-occasion dresses for women, and the company ...
(Date:7/23/2014)... July 23, 2014 Absolute PhysioCare and ... the launch of its custom orthotics and gait scan ... foot abnormalities in order to restore normal body balance. ... cause less fatigue and pain. In addition, Custom orthotics ... in the foot, resulting in relief and greater comfort ...
(Date:7/23/2014)... In his latest blog post at http://www.perwickstrom.com ... Per Wickstrom explains why entrepreneurs should plan for failure. ... he has never failed – and quite miserably at ... “Failure is not the opposite of success; it is ... reveals opportunities and shifts perspectives that, ultimately, are essential ...
(Date:7/23/2014)... 23, 2014 A Forever Recovery, an ... off to a great start and gives them a ... launched a new Internet Addiction section of its website ... to learn that Internet addiction is not just as ... but that it’s trapping more and more victims each ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 In its latest ... programs and believes that having family close by during a ... or not the process is successful, is focusing on a ... all drug and addiction-related dialogues: opiate abuse facts. , The ... , An overview of opiates, and why ...
Breaking Medicine News(10 mins):Health News:Agebc.com Launched Its New Collection of Wedding Dresses 2Health News:Custom Orthotics at Burnaby PhysioCare Now Correct Foot Abnormalities 2Health News:Per Wickstrom’s Latest Blog Post Explains why Entrepreneurs Should Plan for Failure 2Health News:Latest A Forever Recovery Launches Internet Addiction Section on Website 2Health News:Latest Best Drug Rehabilitation Blog Post Focuses on Opiate Abuse Facts 2
... expected to be launched in New Zealand soon, targeting ... Soon, men might also be given cervical cancer vaccines ... to protect themselves against several diseases. ... of cervical cancer prevention. Most cases of cervical cancer ...
... European Union has a huge health problem of having ... ailment in the Union, that costed the bloc’s members, a ... // ,Take a look at the annual ... disease ruled, making a dent of 230 euros on an ...
... that plays a crucial role in deciding if an embryo ... gene develops into a male), could explain the high incidence ... for formation of testes is also produced by Parkinson's affected ... and University of California. ,The SRY gene was ...
... A new research at the National Institutes of Health ... by modifying the lifestyle choices, such as exercise, learning ... published in the journal Alzheimer's & Dementia. ... Affairs for the Alzheimer's Association said that specific combinations ...
... said that the number of children born out of wedlock has ... The ONS Social// Trends survey also found that in 13 other ... ,The survey said that the size of the average UK household ... "Although most children are born to married couples, this substantial rise ...
... than famous, is now going to face some competition. Private ... Canada, having garnered enough support from the several provinces in ... the Quebec government, which intended to remove the ban on ... offered to chip in and pick up costs for such ...
Cached Medicine News:Health News:Men Might Get Their Share of Cervical Cancer Vaccine As Well 2Health News:Sex Determination Gene Blamed For High Incidence Of Parkinson’s In Me 2Health News:Cognitive deterioration in the older generation can be prevented by modifying the lifestyle 2
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
Intended for the quantitative determination of uric acid in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 20 mg/dL (1190 mol/L). Single vial, dry powder reagent....
... A fully automated, random ... over 50 assays available ... tumor marker, therapeutic drug, ... testing can be performed ...
Medicine Products: